LARGE B-CELL LYMPHOMA
Clinical trials for LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests whether adding the drug mosunetuzumab to standard chemotherapy is safe and effective for people with aggressive B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive one of two chemotherapy backbones plus mosunetuzum…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 05:44 UTC
-
New drug combo offers hope for lymphoma patients who Can't have transplant
Disease control OngoingThis study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to previous treatments. Participants must have had 1 to 3 prior treatments and cannot receive high-dose chemotherapy with a …
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control OngoingThis early-stage study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 uses donor immune cells that are modified to target and attack cancer cells. The main goal is to check safety and see if …
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New CAR t therapy targets tough lymphoma in early trial
Disease control OngoingThis early-phase study tests a new type of CAR T cell therapy for adults with large B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better find and attack cancer cells. The main goals are to check safety…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control OngoingThis study tests FDA-approved CAR-T cell therapy in 150 children and adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or large B-cell lymphoma. Participants receive immune cells that are modified to recognize and attack cancer cells. The main goals are to…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug combo aims to improve lymphoma treatment
Disease control OngoingThis study tests whether adding the experimental drug golcadomide to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated high-risk large B-cell lymphoma. About 850 adults will take part, and researchers will compare how long the cancer st…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New cell therapy shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel (YTB323) for several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. About 217 adults will receive this ther…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo shows promise in battling aggressive lymphoma
Disease control OngoingThis study tests whether adding the drug glofitamab to a standard chemotherapy regimen (Pola-R-CHP) can better control large B-cell lymphoma in people who have not yet been treated. About 1,130 participants will receive either the new combination or the standard treatment alone. …
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Experimental 'Natural Killer' cell therapy takes on tough blood cancers
Disease control OngoingThis early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
New imaging technique could predict who benefits from CAR T-Cell therapy
Knowledge-focused OngoingThis study tests a new type of PET scan that looks for a protein called PD-L1 in people with large B-cell lymphoma receiving CAR T-cell therapy. The goal is to see if this scan can predict whether the treatment will work and help tell the difference between active cancer and infl…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated May 17, 2026 05:36 UTC